| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Sar-OH is classified as an amino acid derivative targeting peptide synthesis applications. The sarcosine residue introduces N-methylation into peptide sequences, which can affect peptide conformation, stability, and biological activity. The compound has been reported to have antimicrobial, antitumor, and anti-inflammatory properties. Its mechanism of action involves the inhibition of cell proliferation and the induction of apoptosis in cancer cells. It is a glycine derivative used in research.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies have shown that Fmoc-Sar-OH has antimicrobial, antitumor, and anti-inflammatory properties. The mechanism involves inhibition of cell proliferation and induction of apoptosis in cancer cells. Amino acids and amino acid derivatives like Fmoc-Sar-OH have been commercially used as ergogenic supplements. They affect the release of anabolic hormones and fuel availability. The compound's N-methylated glycine structure influences peptide bioactivity. |
| ln Vivo |
There is no specific in vivo activity data for Fmoc-Sar-OH as a standalone compound. Peptides containing sarcosine residues synthesized using this building block may be evaluated in vivo for various therapeutic applications. N-methylation of peptide backbones can improve metabolic stability and oral bioavailability. Sarcosine-containing peptides have been studied in the context of antimicrobial and anticancer research. Animal studies would be performed on the final peptide products.
|
| Enzyme Assay |
In vitro enzyme/receptor binding protocols for Fmoc-Sar-OH involve its use in SPPS. Standard Fmoc chemistry: the compound is activated with coupling reagents (HATU/HBTU + DIPEA) in DMF and coupled to resin-bound peptides. The N-methyl group can slow coupling kinetics, requiring extended reaction times or repeated couplings. Fmoc deprotection uses 20% piperidine in DMF. Purity is ≥98% by HPLC. Coupling efficiency is monitored by Kaiser test or HPLC.
|
| Cell Assay |
Cell-based protocols for Fmoc-Sar-OH as a building block are not applicable. However, sarcosine-containing peptides can be tested in cellular assays. Peptides are dissolved in DMSO or cell culture medium, sterile-filtered, and added to cells at 0.1-100 µM. Incubation is typically 24-72 hours. Assays include cell viability (MTT), proliferation (BrdU), apoptosis (Annexin V), and specific signaling pathway readouts (Western blot, ELISA). The sarcosine residue can modulate peptide bioactivity.
|
| Animal Protocol |
Animal studies with Fmoc-Sar-OH are not conducted directly. Peptides containing sarcosine residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via IV, IP, or PO routes in appropriate animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard protocols. N-methylation can improve peptide stability and bioavailability. Dosing regimens depend on the peptide's therapeutic application.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-Sar-OH is not applicable as it is a research building block. The compound has molecular weight 311.34 g/mol, formula C₁₈H₁₇NO₄, and LogP of 3.68. It is soluble in DMSO (~100 mg/mL) and shows limited water solubility. It has a melting point of 115-119°C. The Fmoc group is removed under basic conditions during peptide synthesis. The resulting sarcosine-containing peptides may have altered pharmacokinetics due to N-methylation.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-Sar-OH is limited. The compound is for research use only and not intended for human therapeutic use. Standard safety precautions should be observed. Acute toxicity is expected to be low. Store as powder at -20°C for 3 years or 4°C for 2 years. In solvent, store at -80°C for 6 months or -20°C for 1 month. No specific toxicity studies have been reported.
|
| References | |
| Additional Infomation |
Fmoc-Sar-OH (CAS#: 77128-70-2) is also known as N-Fmoc-N-methylglycine, Fmoc-sarcosine, and 2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid. Its molecular formula is C₁₈H₁₇NO₄ and molecular weight is 311.34. It has a purity of ≥98%. It is a glycine analogue used as a building block in Fmoc SPPS. It has antimicrobial, antitumor, and anti-inflammatory properties. It is not approved for therapeutic use.
|
| Molecular Formula |
C18H17NO4
|
|---|---|
| Molecular Weight |
311.3319
|
| Exact Mass |
311.115
|
| CAS # |
77128-70-2
|
| PubChem CID |
688640
|
| Appearance |
White to off-white powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
512.8±29.0 °C at 760 mmHg
|
| Melting Point |
119 °C
|
| Flash Point |
263.9±24.3 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.615
|
| LogP |
3.68
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
430
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(N(C([H])([H])[H])C([H])([H])C(=O)O[H])=O)C([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
ZHKQIADIIYMFOZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H17NO4/c1-19(10-17(20)21)18(22)23-11-16-14-8-4-2-6-12(14)13-7-3-5-9-15(13)16/h2-9,16H,10-11H2,1H3,(H,20,21)
|
| Chemical Name |
2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid
|
| Synonyms |
Fmoc-Sar-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~321.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2120 mL | 16.0601 mL | 32.1203 mL | |
| 5 mM | 0.6424 mL | 3.2120 mL | 6.4241 mL | |
| 10 mM | 0.3212 mL | 1.6060 mL | 3.2120 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
